scispace - formally typeset
E

Eva A. Rog-Zielinska

Researcher at University of Freiburg

Publications -  53
Citations -  1714

Eva A. Rog-Zielinska is an academic researcher from University of Freiburg. The author has contributed to research in topics: Glucocorticoid & Medicine. The author has an hindex of 17, co-authored 44 publications receiving 1131 citations. Previous affiliations of Eva A. Rog-Zielinska include University of Edinburgh & British Heart Foundation.

Papers
More filters
Journal ArticleDOI

Electrotonic coupling of excitable and nonexcitable cells in the heart revealed by optogenetics.

TL;DR: Direct electrophysiological evidence of heterocellular electrotonic coupling in native myocardium is provided and tunneling nanotubes are identified as a possible substrate for electrical cell coupling that may be in addition to previously discovered connexins at sites of myocyte–nonmyocyte contact in the heart.
Journal ArticleDOI

PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation

TL;DR: It is shown that activation of the peroxisome proliferator–activated receptor γ (PPARγ) via pioglitazone treatment protects against heart failure in the Sugen hypoxia rat model of pulmonary arterial hypertension and suggests that targeting PPARγ activation to restore fatty acid oxidation could be therapeutic for pulmonary hypertension and other diseases with altered lipid metabolism.
Journal ArticleDOI

Glucocorticoid receptor is required for foetal heart maturation

TL;DR: It is demonstrated that structural, functional and biochemical maturation of the foetal heart is dependent on glucocorticoid signalling within cardiomyocytes and vascular smooth muscle, though some aspects of heart maturation are independent of GR at these key sites.
Journal ArticleDOI

The Living Scar – Cardiac Fibroblasts and the Injured Heart

TL;DR: A better understanding of fibroblasts' biophysical interactions will help to target scar structure and function, and will facilitate the development of novel therapies aimed at modifying scar properties for patient benefit.